
San Diego-based drug discovery and development company BrainCells Inc. has begun a Phase IIa clinical trial of its innovative depression with anxiety drug, BCI-540.
"We are encouraged by the enthusiasm expressed by our clinical investigators who view BCI-540 as a potential alternative to today's widely prescribed treatments for depression," noted Carrolee Barlow, M.D., Ph.D., Chief Scientific Officer at BCI. "Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels. We are excited about the potential of this compound to change the way mood disorders are treated."
Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. It is thought that most current antidepressants encourage formation of new neurons in the hippocampus by neurogenesis. However, BCI-540 does not act upon serotonin, norepinephrine (noradrenaline), or dopamine pathways as traditional antidepressants do. A previous 6-months trial of the compound for a non psychiatric disorder found side-effects did not differ from those produced by the placebo control.
The twelve-week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80 mg given once or three times daily is effective in the treatment of depression with anxiety versus placebo.
BrainCells Inc in-licensed BCI-540 from Mitsubishi Pharmaceutical Corporation in August 2006.